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Cross talking molecular mechanisms 
in the failing heart: present and future
targets of medical therapy
fibrosis. The transition from apparently compensated
hypertrophy towards negative LV remodelling affects
myocytes and the extracellular matrix by different cellular
mechanisms, which primarily reduce the negative pressure
gradient and ventricular diastolic suction. Ventricular suc-
tion is the vital process that allows rapid ventricular fil l i n g
at low pressures.3 Most of the approaches to treatment of
recent decades were aimed to counteract pressure and vol-
ume overload. Profibrotic neurohumoral responses,
together with increased levels of circulating neurohor-
m o n e s ,4 reactive oxygen species (ROS), and a changing bal-
ance between metalloproteinases and their inhibitors; and
potentially genetic factors are the major molecular mecha-
nisms implicated in the progression of heart failure.4
After myocardial infarction, the necrotic cells lose their
physiological contractile properties, but the abnormal load-
ing conditions involve not only the ischaemic myocardium
but also the border zones of the infarcted area, and, amaz-
ingly, also the remote myocardium. In the clinical setting, in
contrast with the animal model in which the occlusion of one
major vessel is immediately followed by a diffuse ‘compen-
satory’ vasodilatation,5a relevant vasoconstriction takes place
in infarcted and in remote regions, irrespective of prompt
reperfusion of the occluded vessel.6 , 7 In the clinical setting
this vasoconstriction - and consequently the reduction in LV
shortening - is induced by multiple factors6 – 1 0 i n c l u d i n g
ischaemia, necrosis, apoptosis, infla m m a t i o n ,8 ROS forma-
tion, myocytes slippage and distal microembolisation.9
It is likely that the increase in circulating neurohormones
plays a major role. In our clinical observations,6 , 1 0 , 1 1 t h e
intracoronary administration of α-adrenergic blockers
counteracted LV dysfunction and vasoconstriction. When
α-adrenergic blockers were additionally given on top of
adenosine, the coronary flow reserve was improved.1 2
Previous animal studies have shown that distal microsphere
embolisation is followed by adenosine release by the non-
embolised neighbouring vessels. Accordingly also the flo w
improvement seen after PCI and interpreted as postdilata-
tion hyperaemia may be due to distal embolisation.9,12,13 
NEUROHUMORAL ACTIVATION
Both the adrenergic and the renin-angiotensin-aldosterone
systems are activated by ventricular dilation and are respon-
sible for  heart failure.
Up- and down-regulation of adrenergic-receptor
density
Adrenergic receptors (ARs) exist in the myocardium and
mediate many of the physiological responses of heart func-
tion via stimulation by the sympathetic transmitters, nore-
pinephrine and epinephrine.1 4 Adrenergic receptors are
The old heart failure (HF) treatments, which increased
contractility, generally also increased mortality, whereas
neurohumoral antagonism has successfully improved survival.
Nevertheless death rate and disability remain major social
problems, mainly for patients undergoing treatment, either due
to late treatment initiation, inappropriate dosages or lack of
persistence owing to possible side effects. This brief review will
address the neurohumoral overdrive that makes the heart fail
and triggers most, if not all, the changes in molecular
mechanisms recently demonstrated to occur in HF syndrome.
This review will also draw the attention of cardiologists to 
the suggestions for guidelines as to prescribing drugs that
restore normal adrenergic receptors’ density, thus providing 
a simultaneous improvement in other interdependent
mechanisms. 
Molecular mechanisms related to the increase in
circulating neurohormones; some exciting novel heart failure
therapies, such as replacement of the ischaemic or failing
cells with new cardiomyocytes from stem cells; and the
changes of adrenergic signalling by selectively modulating
s p e c i fic molecules, will also briefly be taken into account.
Heart failure (HF) is the final pathway for most of thediseases that affect the heart. In recent decades wehave observed an unprecedented improvement in
mortality and morbidity due to the widespread use of coro-
nary artery bypass graft, thrombolysis in myocardial infarc-
tion (TIMI) and percutaneous coronary interventions
(PCI) in association with medical treatment.1 N e v e r t h e l e s s ,
despite full revascularisation of the epicardial coronary
arteries, HF is still one of the major causes of death in the
population over 65 years of age, since we still lack the full
knowledge of the myriads of molecular mechanisms
responsible for HF progression.  
A recent report shows that the improvement in long-term
mortality in elderly patients after myocardial infarction is
mainly due to the increased use of cardiovascular medication.2
This brief review will focus on some of the molecular
mechanisms interrelated with the sympathetic nervous sys-
tem drive and has the scope of drawing the attention of car-
diologists to the guideline suggestions, in order to induce
patients to follow the prescriptions and tolerate the possible
initial side effects.1 In addition some details will be given on
potential future fields of investigation or potential therapies
that might add to the already vast association of useful drugs.
MYOCARDIAL REMODELLING 
Myocardial remodelling indicates the structural changes of
the ventricular shape by abnormal loading conditions that
become deleterious to the overall cardiac function. Volume
and pressure overload lead to cell death by apoptosis and
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divided into two principal types, alpha- and beta-receptors,
which possess opposite but ‘cross-talking’ effects.1 4 – 1 6 M a n y
subtypes were identified following their response to chem-
icals or drugs and are extensively described elsewhere.1 5 I n
brief, nine subtypes, three subtypes each of α1-, α2-, and
ß-adrenergic receptors were described.1 5 Each type prefer-
entially links to members of a subfamily of G protein. The
number of activated G proteins exceeds the number of cor-
responding receptors and effectors; thus, the activation of
G proteins amplifies signalling by the adrenergic recep-
t o r s .1 7 Receptors’ desensitisation, mediated in part by G-
protein–receptor kinases and ß-arrestins, is involved in
decreasing the ability of agonists to activate adrenergic
r e c e p t o r s .1 7 In heart failure, adrenergic receptors progres-
sively desensitise and, accordingly, the contracting capaci-
ty of myocytes decreases.1 8 , 1 9 Persistent exposure to agonists
can also result in an actual loss of receptors, presumably
through degradation, but this type of receptor down-regu-
lation occurs more slowly. The susceptibility to these ago-
nist-promoted events differs among the various types and
subtypes of adrenergic receptors.1 8 , 1 9
The downregulation of adrenoceptor density in human
HF is a progressive mechanism that in the advanced HF
stages becomes irreversible, whereas in the animal model in
which HF is obtained by pacing, the adrenoceptor density
returns to normal level by week four after cessation of pac-
i n g .1 8 , 1 9 The pathophysiology of adrenoreceptors in
ischaemia and in HF is still mainly unknown. 
In the canine model it is possible to induce HF by mul-
tiple sequential coronary microembolisation.2 0 Distal coro-
nary embolisation is likely to be the major factor that limits
the results obtained after TIMI7, PCI1 2 and PAMI.9
Adrenergic receptor alterations in the clinical setting
The knowledge of receptors endocytosis, i.e., the receptor-
mediated mechanism used by cells for the uptake of macro-
molecules from the extracellular fluid, has recently defle c t e d
the focus on adrenergic receptors that internalise to elicit a
cellular function and subsequently externalise to be ready
to initiate a second endocytosis (Figure 1).2 1 An impairment
of cardiac norepinephrine reuptake through neuronal
norepinephrine transporter promotes depletion of cardiac
norepinephrine stores and local cardiac sympathetic acti-
vation in myocardial ischaemia and in heart failure.2 2
In fact ß-adrenergic receptor kinases (ß ARK1) are ele-
vated in the failing heart and in myocardial ischaemia like-
ly to be triggered by heightened sympathetic nervous system
a c t i v i t y .2 2 , 2 3 It is demonstrated that also the alterations in
myocardial ß-AR signalling present in myocardial
ischaemia mirror those found in chronic HF.2 4
It is now well established that up- and down-regulation
of the receptors - and consequently their availability - play
a key role in cardiomyocytes contraction and in the home-
ostasis of coronary artery tone.2 2 – 2 5 In particular, in hiber-
nating cardiomyocytes, the adrenergic receptors’ density
changes following the severity of ischaemia.2 6 In fact, it was
shown that the density of α-adrenoreceptors progressively
increases in hibernating and non-functional myocardium,
whereas, in contrast, ß-adrenoreceptors decrease in dys-
functional myocardium.2 6
The adrenergic-mediated attenuation of resting myocar-
dial function was also demonstrated in experimental mod-
els of myocardial ischaemia.2 7 – 2 8
Receptors may be targeted to the lysosome for degrada-
tion or recycled back to the cell surface for further rounds
of uptake.2 1 Recent developments using the techniques of
site-directed mutagenesis, cell-free assays and cell fraction-
ation have begun to elucidate the endocytic mechanism, its
dynamics and regulation.2 7 – 2 9
When functional recovery of receptors is absent, as in
ischaemia or in HF, the myocyte contraction and the
response to inotropic drugs does not occur. Evidence from
both neural recordings and measurement of circulating cat-
echolamines clearly documents a central origin for much
of the sympathetic activation in chronic HF.3 0 , 3 2 In HF there
is also an impairment of cardiac norepinephrine reuptake
through the neuronal norepinephrine transporter that pro-
motes depletion of cardiac norepinephrine stores and local
cardiac sympathetic activation (Figure 2).3 0 – 3 2
The mechanisms involved in sympathetic dysfunction
appear to be, in these disorders, multifactorial.4 , 3 0 – 3 2
Alterations in the local production of substances such as
bradykinin, NO, prostaglandins,3 3 and so forth, have all been
implicated as excitatory substances for cardiac and chemore-
ceptor afferents in heart failure. The sympathetic nerve func-
tion is not only regulated by the central nervous system but
also by the target organ. Patients with congestive heart fail-
ure have a chronic and increased activation of the sympa-
thetic nervous system that induces a progressive worsening
of left ventricular dysfunction, and cardiac remodelling. 
Genetic causes and genes polymorphism
The response of the heart to overload or injury is the acti-
vation of intracellular signalling pathways that elicits heart-
failure phenotype that in turn induces myocyte hypertrophy,
re-expression of an embryonic gene pattern, including up-
regulation of structural fetal genes, such as beta-myosin
heavy chain, and down-regulation of adult structural genes,
such as a-myosin heavy chain, and remodelling of the extra-
cellular matrix. These events lead to left ventricular negative
remodelling and progressive myocardial fib r o s i s .3 4
Activation of the renin-angiotensin-aldosterone sys-
tems
Ventricular overloading also activates the renin-
angiotensin-aldosterone system.3 3 , 3 5 Angiotensin II is syn-
thesised directly within the myocardium; probably
exaggerates the activation of metalloproteinases,3 6 a p o p-
Figure 1. Shows a simplified
schema of the dynamic of an
adrenergic receptor and of an
agonist action. Agonist binds to
externalised receptors to give rise
to cell reactions. Then receptors
aggregates, bind to agonist,
internalise and recycle returning
on the cell surface. The lack of
recycling and re-externalisation
alters cell homeostasis and
function, as it occurs in HF or in
the presence of ischaemia.
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totic cardiomyocyte death and increased cytosolic calcium;
and promotes the expression of the profibrotic mediator,
transforming growth factors -β ( T G F -β) expression, thus
further increasing mechanical dysfunction.3 7 , 3 8 M o r e o v e r ,
increased myocardial angiotensin II augments apoptosis in
ventricular myocytes, also by ROS formation.8 C o n v e r s e l y ,
angiotensin-converting-enzyme (ACE) inhibition blocks
T G F -β and lessens myocardial and perivascular fib r o s i s .3 8
Increased angiotensin-II-mediated release of aldosterone
promotes both sodium retention and cardiac fib r o s i s .3 9 T h e
combination of fibrosis and increased cell death leads to a
disorganised, poorly contracting myocardium. 4 0
ROLE OF EXTRACELLULAR MYOCARDIAL MATRIX
The myocardial extracellular matrix (ECM) was once con-
sidered a static structure. Now it is known to be a complex
microenvironment containing a large portfolio of matrix pro-
teins, signalling molecules, proteases and cell types that play
a fundamental role in the myocardial remodelling process.4 1
ECM is synthesised by cardiac fib r o b l a s t s4 2 , 4 3 and main-
tains myocyte orientations throughout the LV free wall.4 1 T h e
collagen synthesis is modulated by metalloproteinase and its
inhibitors. When matrix metalloproteinases inhibitors
increase activity, collagen crosslinks degenerate so that the
hypertrophied left ventricle begins to dilate and causes fib r o-
sis. ECM maintains alignment of myofibrils within the
myocyte through a collagen-integrin-cytoskeleton-myofib-
ril relation. In addition to a fibrillar collagen network, a base-
ment membrane, proteoglycans, and glycosaminoglycans,
the myocardial ECM contains a large reservoir of bioactive
m o l e c u l e s .4 1 It has been demonstrated that the concentration
of bioactive signalling molecules such as angiotensin II (ANG
II) and endothelin -1 (ET-1) are over 100-fold higher with-
in the myocardial interstitium than in plasma.4 1 M o r e o v e r ,
cytokine activation and signalling - such as that for tumour
necrosis factor-α ( T N F -α) - is highly compartmentalised
within the myocardial interstitium. Growth factors such as
T G F -βare stored in a latent form within the myocardial inter-
stitium and thereby form a reservoir of signalling molecules
that directly influence myocardial ECM synthesis and degra-
dation. 
CONTROL ROLE OF THE SYMPATHETIC NERVOUS
SYSTEM IN ACTIVE MOLECULES OVEREXPRESSION
Increased overexpression of biologically active molecules
that are capable of exerting deleterious effects on the heart
and circulation, such as angiotensin II, endothelin, natri-
uretic peptides and TNF-α, are peptide growth factors
and/or cytokines that are produced by a variety of cell types
within the heart, including cardiac myocytes.4 1 – 4 2 D e s p i t e
the fact that biologically active molecules do not have a neu-
roendocrine origin, they are likely to be under the control
of neurohormonal activity.4 3
ROLE OF β-BLOCKERS IN HEART FAILURE 
Beta-adrenergic blockers have a remarkable effect on the
progression of HF, primarily counteracting the deleterious
increase of the sympathetic drive that downregulates adren-
ergic receptors, which are essential for myocytes contraction.
Beta-blockers have a direct beneficial effect on the myocardi-
um, enhancing reverse remodelling. Selected agents that also
block the α-adrenergic receptors induce vasodilatation.4 4 – 4 8
The beneficial effects of these drugs include improvements
in survival, morbidity, ejection fraction, remodelling, qual-
ity of life, the rate of hospitalisation and the incidence of sud-
den death. Beta-blockers should be used in all patients in
stable condition without substantial fluid retention and
without recent exacerbations of heart failure requiring
inotropic therapy. Although the short-term effects of β-
blockers may result in a temporary exacerbation of symp-
toms, their long-term effects are uniformly beneficial. 
ACE INHIBITORS AND ALDOSTERONE ANTAGONISTS 
Angiotensin-converting–enzyme (ACE) inhibitors and
angiotensin-receptor blockers decrease afterload by inter-
fering with the renin–angiotensin–aldosterone system,
resulting in peripheral vasodilatation. They also affect left
ventricular hypertrophy, remodelling and renal blood flo w .
Aldosterone antagonists counteract the effects of aldos-
terone. 
Attenuation or even reversal of left ventricular dilatation
after myocardial infarction and decrease of the incidence of
recurrent myocardial infarction in patients with coronary
artery disease was an unexpected finding. Such benefic i a l
effects were associated with so-called reverse remodelling,
in which the therapy promoted a return to a more normal
ventricular size and shape. The reverse-remodelling process
is a mechanism through which a variety of treatments pal-
liate the heart-failure syndrome.4 9 , 5 0
STATINS
Simvastatin has been shown to be effective in lowering the
incidence of new-onset heart failure, and improving HF
o u t c o m e .5 1 Favourable statins effects may be a result of both
lipid and nonlipid mechanisms affecting endothelial
vasoregulation, and normalisation of sympathetic out-
flo w5 2 that induces pronounced peripheral vasoconstric-
tion, sodium retention, attenuated cardiovascular refle x e s ,
and susceptibility to ventricular arrhythmias and sudden
cardiac death. Statins are shown to be neuroprotective, in
part, by a nitric oxide (NO)-dependent mechanism5 3 a n d
Figure 2. Schema of sympathetic
nerve receptors that regulate the
synaptic release of norepinephrine
at a neuroeffector junction. The
autofeedback loop that regulates
the synaptic reuptake of
norepinephrine (NE) is altered in
advanced HF, and myocyte
function is impaired.
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in part because NO is sympathoinhibitory, and according-
ly lower sympathetic outflo w .54, 55
INFLAMMATION 
I n flammatory response and cytokine elaboration are par-
ticularly active after myocardial infarction8 and contribute
to survival or deaths of myocytes. TNF-α or interleukin-6
acutely regulate myocyte survival or apoptosis and trigger
additional cellular inflammatory response. The triggers of
cytokine release include mechanical deformation, ischaemic
stimulus, ROS and cytokine self-amplification pathways.
Chronically, the presence of cytokines leads to myocyte phe-
notype transition and activation of matrix metallopro-
teinases that modifies interstitial matrix, and increases the
remodelling process. These processes may induce angio-
genesis and cellular regeneration.4 4 Thus, the modulation of
cytokines through current and future therapies could pro-
mote improved healing and cardiac remodelling. 
PROTECTIVE ROLE OF CYCLIC GMP—SILDENAFIL
AS POTENTIAL TREATMENT OPTION 
The inhibitory cardiovascular signals mediated by cyclic
guanosine monophosphate (GMP) modulate adrenergic
e f f e c t s .5 6 Furthermore, genetically increased synthesis of
cyclic GMP inhibits pressure-induced pathological remod-
e l l i n g .5 7 S i l d e n a fil inhibits the breakdown of cyclic GMP and
neutralises many growth pathways to prevent and reverse
hypertrophy and failure induced by aortic constriction.5 7
By cyclic-GMP-induced formation of nitric oxide, sildenafil
might reduce vascular stiffness acting as a systemic vasodila-
tor in patients with heart failure.5 8
THE FUTURE: SEARCH FOR A BETTER TREATMENT
Stem cells
Many clinical problems that occur in patients with heart
failure remain unsolved. A better knowledge of the molec-
ular mechanisms will improve treatment of the HF syn-
drome. Recently the concept of the heart as a post-mitotic
organ was superseded by the notion of the heart as a self-
renewing organ regulated by multipotent cardiac stem cells
capable of regenerating myocytes and coronary vessels
throughout life.5 9 In the past decade, numerous stem cell
studies have shown extrinsic and intrinsic regeneration of
myocytes and coronary vessels. Cardiac stem cell therapy
may become, perhaps in the near future, a novel strategy
for the social problem of heart failure.6 0
Alteration of myocardial adrenergic receptor sig-
nalling to modulate in-vivo cardiac function 
Genetically engineered mouse models have recently pro-
vided the knowledge that in-vivo contractility can be
enhanced via alteration of myocardial adrenergic receptor
(AR) signalling.6 1 Thus genetic manipulation of the AR sig-
nalling system in the heart, including its regulation by
desensitising kinases, represents a novel therapeutic
approach for improving function of the failing heart. In
addition to a gene therapy approach, the discovery of small
molecules to inhibit β ARK1 activity could lead to novel
drugs that might prove more selective in improving per-
formance of the failing heart. 6 2
Cardiac gene delivery
Recent preliminary advances in cardiac gene delivery have
been reported in animal models.6 3 In this context, gene
transfer provides a potential therapeutic modality. Several
interventions, particularly those enhancing sarcoplasmic
calcium transport, show promise in animal models of heart
failure and in myopathic cardiomyocytes derived from
patients.  However, the gap between the basic studies and
clinical gene therapy remains far from being clarified and
early experiments need to be extended to large-animal mod-
els to assess both efficacy and safety. Only time and further
research will tell if these can be successfully extended to clin-
ical practice.
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